Cabot Corp (CBT) CEO Keohane exercises 91,923 options and sells shares at $86.41
Rhea-AI Filing Summary
CABOT CORP President and CEO Sean D. Keohane exercised an employee stock option for 91,923 shares of common stock at an exercise price of $62.24 per share on August 7, 2026. The same day, he sold 91,923 common shares at a weighted average price of $86.4053 per share in multiple transactions at prices ranging from $85.970 to $86.815. The option, which covered 91,923 shares and vested between 2018 and 2020, now has 0 options remaining. Keohane continues to hold 14,263.7411 shares of common stock indirectly through the trustee for the corporation's 401(k) plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and Sale: 91,923 shares ($2.22M approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Keohane Sean D
Role
President and CEO
Sold
91,923 shs ($7.94M)
Approx. gross sale proceeds
$7.94M
Approx. exercise cost
$5.72M
Approx. pre-tax spread
$2.22M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Buy) F2 | 91,923 | $0.00 | $0.00 |
| Exercise | Common Stock | 91,923 | $62.24 | $5.72M |
| Sale | Common Stock F1 | 91,923 | $86.4053 | $7.94M |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 404,134 shares (Direct);
Common Stock — 14,263.7411 shares (Indirect, Through the Trustee for the Corporation's 401(k) Plan)
Footnotes (2)
- F1. The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $85.970 to $86.815, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the Corporation or any security holder of the Corporation, upon request, full information regarding the number of shares sold at each separate price.
- F2. 91,923 shares were subject to the option. The option vested over a three year period as follows: 30% on November 10, 2018, 30% on November 10, 2019, and 40% on November 10, 2020.
Key Figures
Options exercised: 91,923 shares
Option exercise price: $62.24 per share
Shares sold: 91,923 shares
+3 more
6 metrics
Options exercised
91,923 shares
Employee stock option for common stock exercised on August 7, 2026
Option exercise price
$62.24 per share
Exercise price of employee stock option covering 91,923 shares
Shares sold
91,923 shares
Common stock sold on August 7, 2026 following option exercise
Weighted average sale price
$86.4053 per share
Weighted average price for 91,923 shares sold, range $85.970–$86.815
Indirect holdings
14,263.7411 shares
Common stock held through trustee for the corporation's 401(k) plan after transactions
Option expiration date
November 9, 2027
Expiration date of the exercised employee stock option
Key Terms
Employee Stock Option (Right to Buy), weighted average sale price, indirect, vested
4 terms
Employee Stock Option (Right to Buy) financial
"Security title listed as "Employee Stock Option (Right to Buy)" for 91,923 shares"
weighted average sale price financial
"The price reported is a weighted average sale price. These shares were sold"
indirect financial
"Ownership type reported as indirect through the Trustee for the Corporation's 401(k) Plan"
vested financial
"The option vested over a three year period as follows: 30% on November 10, 2018"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did CABOT CORP (CBT) CEO Sean D. Keohane do in this Form 4?
Sean D. Keohane exercised 91,923 stock options at $62.24 per share and sold 91,923 common shares at a weighted average price of $86.4053 on August 7, 2026.
What were the terms of the stock option exercised by the CABOT CORP (CBT) CEO?
The exercised employee stock option covered 91,923 shares at an exercise price of $62.24 per share and was scheduled to expire on November 9, 2027 after vesting in stages from 2018 to 2020.
Was the CABOT CORP (CBT) CEO’s sale under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as an affirmative plan, and the footnotes do not reference any Rule 10b5-1 trading arrangement for these transactions.